10492 results for 'left receptor part'

Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD

Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells t

TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT

Imagine engineering a patient's own immune cells into precision-guided missiles against cancer—cells that can seek out and destroy tumors with remarkable specificity. This is the promise of CAR-T cell

Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate

Understanding Myeloid Cell Networks in Cancer ImmunotherapyImmunotherapy has revolutionized cancer treatment, yet its effectiveness in re-establishing original immune responses post-therapy remains li

A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient

For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th

Animal & Veterinary ELISA Kits | Mouse, Rat, Porcine & More | Assay Genie

Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr

Quick answer A researcher preparing a Human IL-18 ELISA wasn't sure whether the protocol's “300-fold” HRP-Streptavidin step meant adding 40 µL of concentra

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon

Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.

For decades, immunologists believed that only adaptive immunity—the sophisticated system of T cells and B cells—could form lasting memories of past infections. The innate immune system, our body's fir

B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i

For decades, we viewed cancer as a rogue army of cells, a biological glitch driven solely by genetic mutations and metabolic greed. We imagined tumors as isolated fortresses, growing in a vacuum of t

For decades, the battle against cancer has focused on the cellular 'soldiers' and the genetic 'blueprints' within them. Yet, a vast, invisible world of communication exists between these cells—a secr

Understanding PD-1 Blockade in B-Cell Lymphomas Understanding PD-1 Blockade in B-Cell Lymphomas Introduction The programmed cell death prote

Apoptosis Assay Kits | Caspase, Annexin V, TUNEL & JC-1 | Assay Genie

Fast ELISA Kits | Results in Under 120 Minutes | Assay Genie

Custom Multiplex Panels | 415+ Analytes, 5 Species | Assay Genie

Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, part

Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day

The Double-Edged Sword: How Neutrophil Traps Can Both Help and Hinder Cancer's Spread In the intricate battlefield of the human body, the immune system’s foot soldiers, neutrophils, have long been re

The Dynex DS2 platform fully automates the MR-proANP and MR-proADM ELISA assays, streamlining sample processing from loading to detection. Automation ensures consistent assay performance

Cryopreservation of stimulated T cells is a common technique in immunology research, allowing for long-term storage while maintaining their functional viability. Stimulated T cells—especi

What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express

The Role of CD25+FOXP3+CD45RA- Treg Cells in Cancer PrognosisIntroductionRegulatory T-cells (Treg cells) are a specialized subset of T-cells that play a pivotal role in maintaining immune homeostasis

Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune e

Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem

Cell Culture · ProtocolsPassaging Hybridoma Cells: A Detailed GuideHybridomas are productive but temperamental. They grow in suspension, are sensitive to shear and to overgrowth, and — the problem tha

Imagine a battlefield where the enemy doesn't just hide from soldiers—it actively sabotages their weapons. In the tumor microenvironment, cancer cells have evolved a devious strategy: they transfer th

Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a

What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis

What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas

Quick Facts About EnokizumabWhat is Enokizumab?Enokizumab is a monoclonal antibody designed to target interleukin-9 (IL-9), a cytokine involved in inflammatory responses. It has been stu

V-domain Ig suppressor of T cell activation (VISTA) is an emerging immune checkpoint receptor that plays a key role in suppressing T cell activity within the tumor microenvironment (TME).

Imagine a high-stakes game of hide-and-seek where the seeker is your immune system and the hider is a master of disguise: cancer. For decades, we believed the 'wanted' posters for tumor cells were li

Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest

Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does

Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat

A New Dawn in Cancer Treatment: Reprogramming the Immune System's Own Soldiers For decades, the fight against cancer has been a relentless battle of attrition, with treatments like chemotherapy and r

Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease

Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre

Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What

Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons